Sugi Predict

Sugi Predict / Compounds / SCHEMBL3038457

SCHEMBL3038457

SCHEMBL3038457

CCOC(=O)c1cn2c(Cl)nc(Cl)cc2n1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.56
▸ KDM4E B2RXH2 4/20 0.51
▸ POLB P06746 1/20 0.51
▸ GABRA2 P47869 8/20 0.45
▸ GABRB2 P47870 8/20 0.45
▸ RAB9A P51151 4/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ DPP4 P27487 1/20 0.43
▸ DPP8 Q6V1X1 1/20 0.43
▸ DPP9 Q86TI2 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13242132 0.89 GAA (0.56) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL26079081 0.89 GAA (0.56) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL18990731 0.88 GAA (0.54) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL30366650 0.86 GAA (0.53) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL21379846 0.86 GAA (0.53) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL18990153 0.86 GAA (0.53) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL23361271 0.84 GAA (0.51) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL24401299 0.83 GAA (0.50) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL25347009 0.80 GAA (0.61) GAAKDM4EPOLBGABRA2GABRB2
SCHEMBL1283036 0.78 GAA (0.53) GAAKDM4EPOLBGABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MONASH UNIVERSITY (AU) 2023-10-05 — — US disclosed
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-05-11 — — US disclosed
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-05-11 — — US disclosed
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-05-11 — — US disclosed
US-20230096028-A1 BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-03-30 — — US disclosed
US-20220135584-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF REVOLUTION MEDICINES INC (US) 2022-05-05 — — US disclosed
US-20220135584-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF REVOLUTION MEDICINES INC (US) 2022-05-05 — — US disclosed
EP-3930845-A1 BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-01-05 — — EP disclosed
EP-3931195-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-01-05 — — EP disclosed
CN-113767100-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2021-12-07 — — CN disclosed
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
EP-1812439-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-08-01 — — EP disclosed
WO-2006044687-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-04-27 — — WO disclosed
US-20060084650-A1 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084650-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 GAA 1760/4885KDM4E 1350/4885POLB 1015/4885
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 GAA 1760/4885KDM4E 1350/4885POLB 1015/4885
US-20230096028-A1 BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF SOST, SOS1, IQGAP1 GAA 786/4885KDM4E 4422/4885POLB 3571/4885
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MAP2K2, BRPF3, BRDT GAA 3101/4885KDM4E 866/4885POLB 1099/4885
US-20220135584-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 GAA 990/4885KDM4E 4659/4885POLB 3902/4885
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 GAA 990/4885KDM4E 4659/4885POLB 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.